About
Dr Matthew Blunt leads a research team focused on natural killer (NK) cells, novel cancer immunotherapies and haematological malignancies. His research group interacts closely with haematologists at the University Hospital 网络彩票APP下载_澳客彩票网-官方游戏, and with international collaborators from both academia and industry.
Examples of published research include:
- The nuclear export protein XPO1 provides a peptide ligand for natural killer cells (Blunt MD et al, Science Advances, 2024)
- Lymph node associated signals inhibit NK activation against leukemic cells via the immune checkpoint NKG2A (Fisher JG et al, Leukemia, 2023)
- KIR2DS2 expression identifies NK cells with enhanced anti-cancer activity (Blunt MD et al, Journal of Immunology, 2022)
- XPO1 inhibition stimulates NK cell activation against lymphoma cells (Fisher JG et al, Frontiers in Oncology, 2021).
- Development of a novel therapeutic to activate NK cells against cancer (Rettman P, Blunt MD et al, Journal for immunotherapy of cancer, 2021).
- Targeting the PI3K/mTOR pathway in leukaemia (Blunt MD et al, Blood, 2015).
- Identification of IL-4 as a resistance mechanism to idelalisib and ibrutinib in leukaemia (Aguilar-Hernandez M, Blunt MD et al, Blood, 2016 *Co-first author).
- Preclinical evaluation of the dual SYK/JAK inhibitor cerdulatinib alone and in combination with venetoclax in leukaemia (Blunt MD et al, Clinical Cancer Research, 2016).